ARTA
CYTK icon

A.R.T. Advisors’s Cytokinetics CYTK Stock Holding History

A.R.T. Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-44,463
Closed -$360K – 1401
2019
Q1 		$360K Buy
+44,463
New +$327K 0.02% 860
2018
Q2 		– Sell
-48,678
Closed -$350K – 1488
2018
Q1 		$350K Buy
+48,678
New +$417K 0.01% 1081
2017
Q1 		– Sell
-32,461
Closed -$394K – 1474
2016
Q4 		$394K Buy
+32,461
New +$344K 0.02% 847
2016
Q2 		– Sell
-75,197
Closed -$530K – 1409
2016
Q1 		$530K Sell
75,197
-9,600
-11% -$70.1K 0.02% 837
2015
Q4 		$886K Buy
84,797
+44,246
+109% +$434K 0.04% 621
2015
Q3 		$271K Buy
+40,551
New +$277K 0.01% 1070
2015
Q2 		– Sell
-29,045
Closed -$196K – 1522
2015
Q1 		$196K Buy
29,045
+2,034
+8% +$15.2K 0.01% 1236
2014
Q4 		$216K Sell
27,011
-152,761
-85% -$656K 0.01% 1203
2014
Q3 		$632K Buy
179,772
+70,922
+65% +$298K 0.03% 663
2014
Q2 		$520K Buy
+108,850
New +$664K 0.03% 760

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

A.R.T. Advisors's CYTK Position: Q2 2019 in Review

A.R.T. Advisors sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 44,463 shares — an estimated $360K sold.

A.R.T. Advisors first reported a position in CYTK in Q2 2014 and held it in 10 quarters. The position peaked at $886K in Q4 2015. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • A.R.T. Advisors reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 44,463 Cytokinetics shares in Q2 2019, an estimated $360K.
  • A.R.T. Advisors first reported a position in Cytokinetics in Q2 2014 and held it in 10 quarters.
  • A.R.T. Advisors's Cytokinetics position peaked at $886K in Q4 2015.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.